Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04843540 · ClinicalTrials.gov registry record · Phase 1

Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects

A Phase 1 study of Healthy Volunteers, sponsored by Concert Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
22
Enrollment target
1
Study location

NCT04843540: Completed Phase 1 study of Healthy Volunteers, sponsored by Concert Pharmaceuticals.

NCT04843540 is a Phase 1 study of Healthy Volunteers that has completed, run by Concert Pharmaceuticals. The registered enrollment target is 22 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04843540, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Concert Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

This is a Phase 1 open-label study of the effect of rifampin on the pharmacokinetics of CTP-543 in healthy subjects.

Primary Outcome

Area Under the Plasma Concentration-Time Profile

Conditions Studied

Interventions

  • DRUG CTP-543

Study Locations (1)

Florida

  • Clinical Pharmacology of Miami - Miami

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2021-05-19
Est. Completion 2021-07-02
Phase Phase 1
Concert Pharmaceuticals

24 total trials

What the finished NCT04843540 record still lists

NCT04843540 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which CTP-543 is the first listed.

NCT04843540 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT04843540 about?

NCT04843540 is a clinical study titled "Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects". This is a Phase 1 open-label study of the effect of rifampin on the pharmacokinetics of CTP-543 in healthy subjects.

What is the current status of trial NCT04843540?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2021-05-19. Estimated completion is 2021-07-02.

What conditions does trial NCT04843540 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT04843540?

The interventions under investigation include: CTP-543 (DRUG).

Who is sponsoring clinical trial NCT04843540?

This trial is sponsored by Concert Pharmaceuticals, which has 24 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04843540 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04843540's enrollment target sits among peer trials

22 219th of 283 higher than 64 of 283 other Healthy Volunteers trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04843540, the US trial registry maintained by the National Library of Medicine. NCT04843540 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.